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normal liver function and co-infected with
chronic HBV and human immunodeficiency virus
1 (HIV-1)
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Background: Little is known about HBV-specific T-cell responses in chronic Hepatitis B patients (HBV) that are co-
infected with Human immunodeficiency virus type 1 (HIV-1), especially those with normal alanine aminotransferase
(ALT) levels.
Methods: Twenty-five patients with chronic HBV (11 hepatitis B e antigen [HBeAg]-positive, 14 HBeAg-negative)
were enrolled in a cross-sectional study. A longitudinal study as also conducted in which follow-up was done at 3,
12, and 24 months, after acute HIV-1 infection, in 11 individuals who also had chronic HBV. Peripheral blood
mononuclear cells were stimulated with recombinant HBV surface protein (S protein), core protein (C protein) or
gag peptide. IFN-γ-secreting T cells were identified by ELISPOT assay.
Results: In the cross-sectional study, co-infected chronic HBV patients had lower C protein-specific T-cell responses
compared with mono-infected individuals, though the difference was not significant. In co-infected, chronic HBV
patients, the magnitude of C protein-specific T-cell responses was significantly greater in HBeAg-positive subjects
compared to HBeAg-negative subjects (p = 0.011). C protein-specific T-cell responses were positively correlated with
HBV viral load (rs = 0.40, p = 0.046). However, gag-specific T-cell responses were negatively correlated with HIV viral
load (rs = −0.44, p = 0.026) and positively correlated with CD4
+ count (rs = 0.46, p = 0.021). The results were different
in mono-infected individuals. PBMCs from co-infected HBeAg-positive patients secreted more specific-IFN-γ in
cultured supernatants compared with PBMCs from co-infected HBeAg-negative patients (p = 0.019). In the
longitudinal study, S protein- and C protein-specific T-cell responses were decreased as the length of follow-up
increased (p = 0.034, for S protein; p = 0.105, for C protein). Additionally, the S protein- and C protein-specific T-cell
responses were significantly higher in HBeAg-positive patients than in HBeAg-negative patients at 3 and 12 months
after HIV-1 infection (all p < 0.05), but not at 24 months. A positive correlation (trend) was found between C
protein-specific T-cell responses and HBV viral load at 3 and 12 months after HIV-1 infection.
Conclusions: HBV-specific T-cell responses to recombinant HBV core protein were reduced in chronic HBV patients
co-infected with HIV-1. The reduced C protein-specific T cell responses were positively correlated with HBV viral
load in co-infected, chronic HBV patients.* Correspondence: yhp503@126.com
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Patients with Human immunodeficiency virus type 1
(HIV-1) are frequently found to be co-infected with
Hepatitis B virus (HBV). These patients often have a
high prevalence of hepatitis B surface antigen (HBsAg)-
or hepatitis B core antibody (HBcAb)-positive HBV
serological markers due to common infection routes.
Worldwide, it is estimated that 70-90% of HIV-1 pa-
tients have evidence of previous HBV infection and 5-
15% of HIV-1 patients have current HBV infection and
are HBsAg positive. HBV individuals that are co-
infected with HIV seroconvert from hepatitis B precore
antigen (HBeAg) to anti-HBeAg antibody (HBeAb) less
frequently, have higher HBV DNA levels, lower levels of
alanine aminotransferase (ALT) and a history of milder
necroinflammatory activity, compared to those infected
with HBV only [1-4]. In the presence of HIV-1, the
progression of HBV related liver disease is accelerated
and liver related mortality is significantly increased
[5,6]. Additionally, there is an increased risk of persist-
ent chronic infection in individuals infected with HIV-1
who are subsequently infected with HBV [7]. Previous
studies have also shown a relatively high prevalence of
occult Hepatitis B in HIV-1-infected patients, especially
after the withdrawal of antiretroviral therapy. There-
fore, determining the pathogenesis associated with
HIV-1 and HBV interaction, including the modification
of the immune responses, will allow for the develop-
ment of a rational approach for the management of co-
infected individuals.
In persistent HBV monoinfection, there is a reduc-
tion in HBV-specific CD4+ and CD8+ T cells compared
with individuals that have successfully cleared the in-
fection. It has been suggested that HBeAg plays a role
in facilitating HBV persistence by depleting HBeAg-
and HBcAg-specific Th1 CD4+ T cells [8]. The reduc-
tion in antigen burden following anti-HBV treatment
may reduce T cell tolerance and exhaustion, allowing
for a more efficient HBV-specific T-cell and B-cell im-
mune response against either HBeAg and/or HBsAg
[9]. Many previous studies have focused on the alter-
ation of immune responses in HIV/HBV patients with
abnormal liver function and lower CD4 counts, how-
ever little is known about individuals with milder liver
disease that have normal levels of ALT and higher
CD4 counts. In the present study, we examined
whether HBV-specific T-cell responses in chronic HBV
patients could be influenced by the presence or ab-
sence of HBeAg or by the level of HBV DNA, in the
presence of HIV-1. Recombinant S and C proteins
were used as a stimulus, in both cross-sectional and
longitudinal studies, to assess changes in the HBV-
specific total T-cell responses in chronic HBV patients
with HIV-1 co-infection.Results
Patient characteristics
In cross-sectional study, demographic and clinical details
of 25 co-infected chronic HBV patients and 16 mono-
infected chronic HBV patients are summarized in Table 1.
All co-infected chronic HBV patients had normal liver
function, as determined by ALT, AST, and TBIL analysis,
within two years of observation. The HIV/HBV co-infected
patients mainly included high-risk men-who-have-sex-
with-men (MSM). The HBV viral load in the co-infected,
chronic HBV patients was comparable to that of the
mono-infected, chronic HBV patients. HBV viral load was
not correlated with HIV viral load in co-infected, chronic
HBV cases. Demographic and clinical details of patients
with previous HBV infection, who were co-infected with
HIV (n = 14) and who were not co-infected with HIV
(n = 16), are summarized in Table 2. HIV patients that had
previous HBV infection mainly included high-risk MSM,
and had normal liver function, as determined by ALT,
AST, TBIL analysis, within two years of observation.
The HBV viral load in co-infected patients that had
been previously infected with HBV was comparable to
that of mono-infected patients that had been previously
infected with HBV.
In the longitudinal study, 11 individuals with acute
HIV-1 and chronic HBV infection had normal levels of
ALT, AST and TBIL during the 2-year follow-up (Sub-
ject demographic and clinical details are summarized in
Table 3).
In the cross-sectional study, HBV-specific T-cell responses
in co-infected individuals were decreased compared to
mono-infected individuals
There was no significant difference in the response fre-
quency to C protein when comparing co-infected, chronic
HBV patients and mono-infected, chronic HBV patients
(22/25 and 15/16 responded to C-protein, respectively).
The magnitude of the C protein induced HBV-specific T-
cell responses in co-infected, chronic HBV patients was
lower than in mono-infected, chronic HBV patients, how-
ever the difference was not statistically significant (p >
0.05; Figure 1 left). On the other hand, in co-infected,
chronic HBV patients, gag-specific T cell responses were
the highest with all 3 stimuli, including S protein, C pro-
tein and gag peptide (p = 0.0004). Gag-specific T cell
responses were also higher than S protein- and C protein-
specific T cell responses (all p < 0.05; Figure 1 left). In
mono-infected, chronic HBV patients, the magnitude of C
protein-specific T cell responses was greater than that of S
protein-specific T cell responses (p < 0.0001; Figure 1 left).
The response to C protein was less frequent in HIV
patients that had previous HBV infection, compared to
patients that had previous HBV infection but who did
not have HIV (9/14 and 15/16 responded to C protein,
Table 1 Demographics of chronic HBV patients
Parameter Single HBV infection HIV/HBV coinfection
HBeAg+ HBeAg- P value HBeAg+ HBeAg- P value
No. of Subjects 8 8 11 14
Gender(no. male/female) 7/1 6/2 NSa 11/0 13/1 NSa
Age [median (range)] (yr) 36 (22-60) 38 (25-67) NSb 34 (23-40) 32 (25-56) NSb
ALT [median (range)] (U/L) 19.2 (6.1-53)c 23.7 (12.2-40) NSb 22.4 (13.5-58)c 19.2 (13.7-38) NSb
HBV DNAd [median (range)] 7.71 (0-9.04) 1.04 (0-4.32) <0.01 6.85 (0-8.51) 1.35 (0-8.98) <0.01
HIV RNAd [median (range)] NA NA 4.8 (0-5.4) 4.98 (0-5.9) NSb
CD4 count [median (range)] (cells/ul) NA NA 452 (211-862) 332 (122-704) NSb
NS not significant, NA not applicable, aFisher’s exact test; bMann-Whitney U test; conly one patient had an ALT >40 U/L; dlog10,
+postive; -negtive.
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specific T-cell responses was significantly weaker in in-
dividuals that had been previously infected with HBV
and who were co-infected with HIV compared to those
who were not co-infected with HIV (p = 0.003; Figure 1
right), however there was no significant difference
between these groups in specific T-cell responses to S
protein. The median number of total T cells was com-
parable in co-infected and mono-infected individuals
that had previous HBV infection (1346[539–3463]/uL
vs. 1361[689–2116]/uL, respectively). Similarly, the total
T cell percentage was not significantly different between
these two groups. The fact that total T cell number and
percentage were not decreased, and that C protein-
specific T cell responses were decreased, implies that
HBV-specific T cell responses may be impaired in the







No. of patients 16 14
Gender (no. male/female) 9/7 13/1 0.039a
Age
[median(range)] (yr) 31 (23-46) 33 (23-54) NSb
ALT
[median(range)] (U/L) 13(4-30) 15.5 (3-50)c NSb
HBV DNAd
[median(range)] <500 <500 NSb
HIV RNAd
[median(range)] NA 4.45 (0-4.93) NA
CD4 T cell count
[median(range)] (cells/ul) NA 323 (76-640) NA
NS not significant, NA not applicable, aFisher’s exact test; bMann-Whitney U
test; conly one patient had an ALT >40 U/L; dlog10.HBV viral load was correlated with the magnitude of
HBV-specific T-cell responses in chronic HBV patients
co-infected with HIV
To analyze whether HBV viral load could affect the mag-
nitude of HBV-specific T-cell responses in co-infected,
chronic HBV patients, 25 subjects were divided into two
groups according to the lower limit of the HBV viral load
(lower detection limit of 500 copies/mL). As shown in
Figure 2B, the magnitude of C protein-specific T-cell re-
sponses was significantly greater in subjects with an HBV
viral load >500 copies/mL compared to subjects with an
HBV viral load <500 copies/mL (p = 0.023). This differ-
ence was not observed in chronic HBV patients without
HIV coinfection.
The relationship between HBV viral load and the
magnitude of HBV-specific T-cell responses was also
analyzed in the 25 co-infected, chronic HBV patients.
As shown in Figure 2A, the C protein-specific T-cell re-
sponses were significantly positively correlated with
HBV viral load (rs = 0.40, p = 0.046). However, the mag-
nitude of the HBV-specific T-cell response was not cor-
related with CD4+ T cell count or HIV viral load. The
magnitude of gag-specific T-cell response was positively
correlated with CD4+ T cell count (rs = 0.46, p = 0.021;
Figure 2C), but negatively correlated with HIV viral
load (rs = −0.44, p = 0.026; Figure 2D). Gag-specific T
cell responses were significantly lower in co-infected,
chronic HBV patients with an HIV viral load >5(log10)
than in co-infected, chronic HBV patients with an HIV
viral load <5(log10) (p = 0.005), though the difference in
HBV-specific T-cell response was insignificant between
these two groups. These data indicate that HBV-specific
T-cell responses are higher in patients with higher HBV
viral loads, but gag-specific T-cell responses are weaker
in patients with lower CD4+ counts and higher HIV
viral loads.
However, HBV-specific T-cell responses were not re-
lated to HBV viral load in mono-infected, chronic HBV
patients.
Table 3 Demographics of individuals with chronic HBV and acute HIV-1 co-infection
v1 v2 v3
Patient HBeAg HBV DNAa HIV RNAa CD4 count HBV DNAa HIV RNAa CD4 count HBV DNAa HIV RNAa CD4 count
AHI01 pos 8.45 5.66 376 7.38 5.66 212 3.52b <ldlb 376
AHI02 pos 6.54 4.55 533 7.43 4 298 7.76 ND 405
AHI03 neg <ldl 3.89 213 <ldl ND 192 <ldl ND 189
AHI04 pos 7.71 3.75 345 8.2 4.47 275 8.4 ND 342
AHI05 pos 9.04 5.72 363 8.32 ND 292 7.14 ND 363
AHI06 neg <ldl 2.23 361 <ldl ND 345 <ldl ND 221
AHI07 pos 8.14 6.1 412 8.45 ND 329 7.54 ND 293
AHI08 neg <ldl 4.92 308 <ldl 4.67 365 <ldl ND 395
AHI09 neg <ldl 3.39 922 <ldl 3.3 862 <ldl ND 692
AHI10 neg <ldl 6.31 380 <ldl ND 464 <ldl ND 243
AHI11 neg <ldl 5.62 221 <ldl ND 445 <ldl ND 445
pos HBeAg positive, neg HBeAg negative; v1, 2, 3: followed up on 3rd, 12th, 24th month post acute HIV-1 infection; alog10;
bHAART with AZT/3TC/LPVr; ldl lower
limit of detection, ND not done.
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presence of HBeAg
HBV-specific T-cell responses to the presence of HBeAg
were examined in co-infected, chronic HBV patients since
HBeAg is an immunotoleragen [8]. Subjects were divided
into HBeAg negative and HBeAg positive groups. The mag-
nitude of the C protein-specific T-cell response was no dif-
ferent in HBeAg-positive, mono-infected, chronic HBV
patients than in HBeAg-negative, mono-infected, chronic
HBV patients (p > 0.05; Figure 3A right). In contrast, the
magnitude of the C protein-specific T-cell response was sig-
nificantly greater in HBeAg-positive, co-infected, chronic
HBV patients than in HBeAg-negative, co-infected, chronic
HBV patients (p = 0.011; Figure 3A left).Figure 1 Magnitude of HBV-specific T-cell responses induced in HBV
right, previous HBV infection, HIV+, co-infected with HIV; HIV-, not co-infect
stimulated by gag peptide pool.Cytokine responses in cultured supernatants of PBMCs
from co-infected, chronic HBV patients
To further ascertain whether HBeAg-positive, co-infected,
chronic HBV patients have higher cytokine productivity
compared to HBeAg-negative, co-infected, chronic pa-
tients, the levels of IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF,
TNF-α, and IFN-γ secreted by PBMCs, stimulated with
recombinant C protein, were measured in cultured super-
natant. The level of IFN-γ secreted by HBeAg-positive
patients was significantly higher than that secreted by
HBeAg-negative patients (92.09[0.02 ~ 186.21]pg/mL vs.
28.33[0.02 ~ 80.22]pg/mL, respectively; p = 0.031). More-
over, the stimulation in index for cytokine IFN-γ was
significantly higher for HBeAg-positive patients than forpatients with and without HIV infection. Left, chronic HBV infection;
ed with HIV. s: stimulated by S protein; c: stimulated by C protein; gag:
Figure 2 Correlation of various HBV and HIV associated variables. (A) Correlation of HBV viral load and HBV-specific T-cell responses elicited
by chronic HBV patients co-infected with HIV. (B) Comparison of HBV-specific T-cell responses induced by HBV-infected patients with HIV
coinfection grouped by HBV viral load (<500 copies/mL or >500 copies/mL). The relation of CD4 count (C) and HIV viral load (D) on gag-specific
T-cell responses elicited by chronic HBV patients co-infected with HIV.
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ever, there were no significant differences in stimulation
indices for IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, or
TNF-α among the two subgroups.
In the longitudinal study, HBV-specific T-cell responses
were lower in patients with chronic HBV infection with
disease progression
The magnitude of HBV-specific T-cell responses was an-
alyzed in 11 subjects that had been diagnosed as havingFigure 3 Comparison of HBV-specific cell responses in the presence o
ELISPOT assay; (B) Cytokine IFN-Y responses in cultured supernatants of PB
HBeAg(+): HBeAg-positive subjects; HIV+: HIV co-infected; HIV-: not co-infecacute HIV-1 infection and chronic HBV infection concur-
rently. As shown in Figure 4, S protein- and C protein-
specific T-cell responses decreased as the length of follow-
up increased (p = 0.034, for S protein; p = 0.105, for C
protein; Figure 4A). S protein- and C protein-specific T-
cell responses were significantly higher at 3 months after
HIV infection than at 24 months after HIV infection (all
p < 0.05; Figure 4A). Furthermore, the magnitude of C
protein-specific T-cell responses was positively correlated
with the levels of HBV DNA at 3 and 12 months post-r absence of HBeAg. (A) C protein-specific T-cell responses elicited in
MCs stimulated by C protein. HBeAg(−): HBeAg-negative subjects;
ted with HIV.
Figure 4 HBV-specific T-cell responses induced in co-infected, chronic HBV patients followed up 3, 12, and 24 months after the onset
of acute HIV-1 infection. (A) the difference of HBV-specific T-cell responses elicited at different time points; (B) comparison of HBV-specific T-cell
responses in the presence or absence of HBeAg; (C) correlation between C protein-specific T-cell responses and HBV viral load 3 months after the
onset of acute HIV-1 infection; (D) correlation between C protein-specific T-cell responses and HBV viral load 12 months after the onset of acute
HIV-1 infection; *p < 0.05 (Figure 4B); HBeAg-: HBeAg negative; HBeAg+: HBeAg positive.
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p = 0.008; Figure 4D; respectively). Given the effects of
HBeAg as an immunotoleragen, the relationship of the
presence or absence of HBeAg to the HBV-specific T-cell
response was also investigated. We found that the magni-
tude of S and C protein-specific T-cell responses in
HBeAg-positive individuals was significantly higher than
in HBeAg-negative patients at 3 and 12 months after HIV
infection (all p < 0.05; Figure 4B), however there was no
difference between HBeAg-positive and -negative patients
at 24 months after HIV infection.HBV-specific T-cell responses, stimulated by S and C
proteins, are mediated by CD4+ and CD8+ T cells
To identify the specific T-cell responses induced by a
stimulus, CD4+ and CD8+ cells were isolated from
PBMCs and an ELISPOT assay was performed. CD4+ T
cells induced approximately 70-80% of the HBV-specific
T-cell responses and CD8+ cells induced approximately
20-30% of the HBV-specific T-cell responses. In contrast,
CD8+ cells induced about 96% of the gag-specific T-cell
responses, but CD4+ cells induced very little of the gag-
specific T-cell responses.Discussion
In the cross-sectional study, HBV-specific T-cell re-
sponses in chronic HBV patients, co-infected with HIV,
were described. Specific T-cell responses, induced by S
protein, were lower than specific T-cell responses in-
duced by C protein regardless of whether the subject
had an HIV coinfection. This is consistent with the pre-
vious studies that showed that chronic HBV infection is
generally associated with a narrow HBV-specific response,
with the dominant responses often directing the core pro-
tein [10,11]. Overall, in the co-infected, chronic HBV pa-
tients, HBV-specific T-cell responses were weaker than in
the mono-infected patients, though the difference was not
significant. Mono-infected, chronic HBV patients had sig-
nificantly weaker C protein-specific T-cell responses com-
pared to those without HIV who were previously infected
with HBV (p = 0.021, data not shown). However, the mag-
nitude of C protein-specific T-cell response was compar-
able in co-infected, chronic HBV patients and individuals
that had HIV who were previously infected with HBV
(p > 0.05, Figure 1). HBeAg has been described as an im-
munologic toleragen, however it is not clear whether
HBeAg has suppressive effects on the immune response
to HBV in the presence of HIV-1. We found no significant
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HBeAg-positive patients with HIV-1 and HBeAg-positive
patients without HIV-1. However, co-infected, HBeAg-
positive patients had greater HBV-specific T-cell responses
than co-infected, HBeAg-negative patients. Furthermore,
there was no relationship between C protein-specific T-
cell responses and the level of HIV RNA or CD4 count in
co-infected, HBeAg-positive patients (data not shown).
Based on these observations, it appears that HBeAg does
not have suppressive effects on HBV-specific T-cell re-
sponses in the presence of HIV-1.
The magnitude of HBV-specific T-cell responses was
positively correlated with the level of HBV DNA in co-
infected, chronic HBV patients. However, this was not
the case in mono-infected, chronic HBV patients. Simi-
lar results were observed were in the longitudinal study.
Therefore, we hypothesize that the greater HBV-specific
T-cell responses seen in chronic HBV patients with
HIV-1 may be related to higher levels of HBV DNA.
This observation is contradictory to previous studies that
indicating that a reduction in HBV viral load may lead
to a loss of HBV anergy in chronic HBV patients [12,13].
One possible explanation for this discrepancy is that the
anergy to HBV seen in our study may have been partly
activated by HIV-1 co-infection. An alternative explan-
ation is that HBV-specific T cells may migrate from the
liver to the periphery in the presence of HIV-1, as ob-
served with antiviral HBV therapy [14], however the pre-
cise reason(s) and mechanism(s) need to be explored.
We found that HBeAg-positive patients with higher levels
of plasma HBV viral load, had greater HBV-specific T-cell
responses than HBeAg-negative patients with no or very
low levels of HBV viral load. Conversely, in mono-infected,
chronic HBV patients, there was no difference in HBV-
specific T-cell responses between HBeAg-positive and -
negative patients (Figure 3), despite significant differences
in HBV DNA levels. This finding was further confirmed by
data showing that cultured supernatants from HBeAg-
positive patients contained more specific-IFN-γ than that
from HBeAg-negative patients, although there was no dif-
ference in levels of IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, or
TNF-α between HBeAg-positive and -negative patients.
Additionally, we found that HBeAg-positive individuals had
stronger HBV-specific T-cell responses than HBeAg-
negative patients at 3 and 12 months after the onset of
acute HIV-1 infection. These findings are contradictory to
the Chang et al. study which reported that the magnitude
of the HBV-specific IFN-γ –positive CD8+ T-cell response
was not significantly different between HBeAg-positive and
-negative patients in HIV/HBV co-infected, ART naïve pa-
tients [15]. The distinct immunogenicity of stimulus anti-
gens used in the two studies may have led to the different
outcomes. Chang et al. [15] used a 15 amino acid peptide
pool of four proteins, however 14–22 amino acid peptidesare typically used to induce either CD4+ or CD8+ T-cell
responses [16] and mainly induce a CD8+ T-cell response
[17]. Recombinant whole protein can be used to detect
CD4-mediated responses and a limited CD8-mediated re-
sponse [16,18]. In this study, HBV-specific T-cell responses
were not only mediated by CD4+ T-cells but also by
CD8+ T-cells, as described by Kalyuzhny et al. [16],
when recombinant protein was used as the stimulus. An
alternative explanation is that the different disease sta-
tuses may have contributed to the different outcomes.
Patients in the present study were considered to have
mild disease, had normal ALT levels for at least two
years and higher CD4 counts, however the patients in
the Chang study had more severe disease with higher
ALT levels and lower CD4 counts.
In chronic HBV infection, ALT is considered a marker
of hepatic necrosis and inflammation. A lower ALT level
reflects less hepatocyte destruction, which contributes to
weak HBV-specific T-cell responses [19,20]. In the
current study, the co-infected, chronic HBV patients had
normal ALT levels during the two years of observation.
One of possible explanation is that the HBV-specific T-
cell responses were weak. In fact, C protein-specific T-
cell responses in co-infected, chronic HBV patients were
much weaker than in individuals who had been previously
infected HBV, but did not have HIV (p = 0.005, data not
shown). Moreover, the impaired quality of HBV-specific
CD8+ T-cells [15] and concurrent loss of CD4+ cells in co-
infected, chronic HBV patients could result in HBV virus
not being cleared, thus prolonging the chronic HBV infec-
tion. Nevertheless, the biological significance of these find-
ings and their association with normal liver function and
clinical progression remains to be determined.
Previous studies have reported that individuals recover
from HBV infection by acquiring specific immunity to
HBV. In the current cross-sectional study, we also found
that individuals who had been previously infected with
HBV (without HIV co-infection) had stronger HBV
specific T-cell responses. However, HBV-specific T-cell
responses in individuals previously infected with HBV
were exceptionally lower in the presence of HIV-1
(Figure 1); the precise reason(s) and/or mechanism(s)
for this need to be analyzed. As observed in the cross-
sectional study, CD4+ cells mainly induced C protein-
specific T-cell responses. Chang et al. [21] reported that
HBV-specific CD4+ T cells were reduced in HIV/HBV
co-infected, chronic patients that received HBV anti-
retroviral therapy. Thus, we believe that the loss of CD4
+ T cells could lead to a significantly decreased CD4-
specific immune response to HBV. On the other hand,
since CD4+ T- cells are required to sustain CD8+ cyto-
toxic T-cell responses during chronic viral infection
[22-24], the depletion of CD4+ T-cell function may cause
a reduction in HBV-specific CD8+ T-cell responses.
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leukocyte antigen (HLA)-A2-restricted HBV-specific (core
18–27) CD8+ T-cell response in previously infected HBV
subjects who were HIV-positive compared with previously
infected HBV subjects who were HIV-negative. Therefore,
it is thought that the decrease in both HBV-specific CD4+
and CD8+ T-cell responses may account for the weak
HBV-specific T-cell responses in individuals with HIV who
were previously infected with HBV. Furthermore, the
shortage of HBV antigen may be another factor leading to
the lower HBV-specific T cell responses in individuals with
HIV who had been previously infected with HBV. The re-
duction in HBV-specific T-cell responses could account for
the relatively high prevalence of occult Hepatitis B in HIV-
infected patients, especially after withdrawal of HAART
[26]. Although the level of plasma HBV DNA was un-
detectable in the current study in individuals with HIV that
had been previously infected with HBV, continuous visits
would be required to monitor clinical progression.
There were limitations in the present study. First, we
did not know whether co-infected, chronic HBV patients
in the cross-sectional study acquired HBV infection prior
to HIV infection. However, based on previous epidemio-
logical studies of HBV infection in China, it is highly likely
that most of the individuals in cross-sectional study ac-
quired HBV at birth or in early childhood. Patients with
HIV in this study were infected as an adult via the route
of homosexual contact. Thus, it is reasonable to assume
that the individuals in the cross-sectional study were
infected with HIV subsequent to HBV. Secondly, we were
not able to collect accurate data regarding the time of
HBV acquisition in cross-sectional study and could not
take into account potential differences in the duration of
HBV infection among the mono-and co-infected patients.
Overall, the HBV-specific T-cell responses in co-infected,
chronic HBV patients decreased with disease progression
and were positively correlated with HBV viral load. The
HBV-specific T-cell responses significantly lower in indi-
viduals with HIV who had been previously infected with
HBV compared with individuals not co-infected with HIV.
Although almost all co-infected, chronic HBV patients
had normal liver function in this study, longer follow-up
studies of subjects with HIV/HBV co-infections are re-
quired to determine the kinetic changes in HBV-specific
immune responses and to monitor the disease progression
in order to come up with effective approaches to manage
those with HIV/HBV co-infections.
Methods
Subjects
In the current study, 39 patients infected with HIV-1 were
recruited from Beijing Youan Hospital, Capital Medical
University, China, to participate in a cross-sectional study.
A total of 25 patients had chronic HBV and 14 had beenpreviously infected with HBV. Patients had no history of
treatments for either HIV or HBV. The control group was
comprised of 32 individuals that were not infected with
HIV-1; 16 subjects had chronic HBV and 16 subjects had
been previously infected with HBV. All subjects were
older than 18 years of age and were negative for hepatitis
C virus antibody. In the chronic HBV patients, HBsAg
was positive for >6 months prior to analysis. Exclusion
criteria included hepatocellular carcinoma, autoimmune
liver disease, and liver cirrhosis. Patients that had previous
HBV infection were negative for HBsAg, positive for
HBsAb, either positive or negative for HBeAb, and posi-
tive for HBcAb.
A total of 11 individuals with acute HIV-1 and chronic
HBV infection, who had been HBsAg positive for >5 years,
were enrolled in a longitudinal study. Follow-up was done
in these patients at 3, 12, and 24 months after the onset of
acute HIV infection. Signed consent was obtained from all
subjects with the approval of the institutional ethics com-
mittee and the study was in compliance with the Declar-
ation of Helsinki.Human interferon (IFN)-γ ELISPOT assay
Peripheral whole blood was obtained from all subjects
and peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation with Ficoll
Lymphoprep (Axis –Shield PoC AS, Oslo, Norway). Iso-
lated PBMCs were kept in liquid nitrogen. After thawing,
PBMCs were incubated at 37°C in 5% CO2 overnight.
PBMCs (2.0 × 105) were pulsed with 4 μg/mL recombin-
ant Hepatitis B surface protein and recombinant Hepatitis
B core protein (ARP, American Research Products,
Inc. ™, USA), respectively, and were tested using a stand-
ard Human IFN-γ ELISPOT assay, in duplicate wells, as
described previously [27]. PBMCs (2.0 × 105), from sub-
jects with HIV infection, were pulsed with 1 μg/mL gag
peptide pool (comprised of 61 peptides covering the
whole gag protein). In brief, assays were carried out in
96-well MultiScreen filter plates (Millipore) coated with
15 μg/mL anti–IFN-γ mAb 1-DIK (Mabtech AB, Nacka,
Sweden). Three μg/mL phytohemagglutinin (PHA)
(final concentration) was used as a positive control and
the negative control wells were stimulated with RPMI
1640 containing 10% FCS. Plates were incubated at 37°C
in 5% CO2 for 16 h. Spot enumeration was performed
with an ELISPOT reader system (Antai Yongxin Med-
ical Technology, Beijing, China). To quantify antigen-
specific responses, mean spots of the control wells were
subtracted from the positive wells, and results were
expressed as spot-forming cells (SFC) per 106 PBMCs.
Responses were considered positive if results were at
least twice the mean of the duplicate negative control
wells and >30 SFCs/106 PBMCs.
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CD4+ or CD8+ T cells were isolated from PBMCs using the
Dynabeads CD4 kit or Dynabeads CD8 kit (Invitrogen
Dynal As, Oslo, Norway), according to the manufacturer’s
instructions. 2.0 × 105 CD4+ or CD8+ T-cells were pulsed
with 4 μg/mL recombinant Hepatitis B surface protein,
recombinant Hepatitis B core protein (ARP, American
Research Products, Inc.™, USA), or with 1 μg/mL of gag
peptide pool, and were tested using the standard human
IFN-γ ELISPOTassay in duplicate wells as above described.Cytokine responses in cultured supernatants
Samples of PBMC supernatants, from chronic HBV pa-
tients co-infected with HIV, were stimulated with 4 ug/
mL recombinant C protein. Cultured supernatants were
harvested after 2.0 × 105 PBMCs were stimulated, over-
night. The negative control well was not stimulated with
recombinant C protein but with RPMI 1640 containing
10% FCS. Levels of cytokines in the cultured superna-
tants, including IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF,
TNF-α, and IFN-γ, were detected using the Bio-Plex
Pro™ Human Cytokine Grp I Panel 8-plex kit from Bio-
Rad® (magnetic beads, Luminex®, USA). The outcome was
determined using the index of stimulation (IS) to display
the cytokine level of stimulated well. The index of stimula-
tion was taken as the cytokine level of the stimulated well
minus the cytokine level of un-stimulated well divided by
the cytokine level of un-stimulated well.HBV DNA and HIV-1 RNA quantification
HBV DNA was quantified using a domestic HBV DNA
assay kit (KeHua Biological Technological Corporation,
Beijing, China), according to the manufacturer’s instruc-
tions (lower limit of detection, 500 copies/mL). HIV RNA
was quantified using the Roche RT-PCR assay according
to the manufacturer’s instructions (Easy Q; Roche; lower
limit of detection, 40 IU/mL).Graphing and statistical analysis
Graphpad Prism 5 software was used to graph and analyze
the data and P < 0.05 was regarded as statistically signifi-
cant. Proportion of subjects by gender was determined
using Fisher’s exact test. Comparison of age, HBV DNA,
CD4+ T-cell count, and the magnitude and frequency of
specific T-cell responses between the two groups was de-
termined using the Student’s t test for parameter variables
or the Mann–Whitney U test for non-parameter variables.
The correlation between HBV-specific T-cell responses
and HBV DNA or CD4+ T-cell count was determined
using Spearman’s correlation analysis.
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